Version history

{
  "session_id": "sess_SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c_task_9aae8fc5",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "scidex.core.llm.complete",
  "action": "assess",
  "content": "# Feasibility Assessment: Neuronal Autophagy Resistance Mechanisms in ALS\n\n## Executive Summary\n\nOf the five proposed hypotheses, the SKEPTIC's critical evaluation substantially weakens three (H1, H2, H5) through mechanistic confounds and non-uniqueness arguments. Two mechanisms (H3, H4) survive rigorous critique and warrant prioritized investigation, though each faces distinct clinical development obstacles.\n\n---\n\n## Hypothesis 1: mTORC1-TFEB/TFE3 Axis\n**Survival Status: Questionable**\n**Revised Confidence: 0.45-0.50** (post-SKEPTIC downgrade to 0.58 appears optimistic)\n\n### Druggability: MODERATE\n| Modality | Examples | BBB Penetration | Clinical Stage |\n|----------|----------|-----------------|----------------|\n| mTORC1 inhibitors | Rapamycin, Everolimus, Torkinib | Poor-moderate | Approved (other indications) |\n| TFEB activators | Small molecules (un-named) | Unknown | Preclinical |\n| Combination | mTORi + lysosomal boosters | Variable | Exploratory |\n\n**Core Problem:** Drugging mTORC1 to activate TFEB assumes TFEB nuclear translocation is rate-limiting. If downstream lysosomal acidification (H3) is the true bottleneck, mTOR inhibitors will show autophagic flux improvement on canonical readouts (LC3-II, p62 turnover) without functional benefit—explaining the \"attenuated neuronal response\" without establishing causality.\n\n### Biomarkers & Model Systems: ROBUST\n- **Readouts:** Nuclear:cytoplasmic TFEB ratio (confocal microscopy), CLEAR gene panel (qPCR), p-S6K1 S240/244\n- **Model Systems:** FANN-isolated motor neuron nuclei (SOD1G93A) are technically feasible; iPSC-derived motor neurons with TFEB-GFP reporters are well-established\n- **Falsifying Experiment Feasibility:** AAV delivery of constitutively nuclear TFEB (S211A/S122A) to spinal cord motor neurons is achievable within 18 months\n\n### Clinical Development Constraints: SIGNIFICANT\n- **Indication alignment:** Chronic ALS treatment requires sustained dosing; rapamycin analogues carry metabolic and immunosuppressive burden incompatible with ALS patient population\n- **Target engagement assays:** No validated human TFEB nuclear translocation biomarker exists for CSF or blood\n- **Patient stratification:** No genomic marker identifies which patients have mTORC1 hyperactivation vs. downstream blocks\n\n### Safety: CONCERNING\n| Risk | Severity | Monitoring Requirement |\n|------|----------|------------------------|\n| Immunosuppression | High | CBC, infection surveillance |\n| Metabolic dysfunction | Moderate | Glucose, lipid panels |\n| Off-target lysosomal inhibition | Moderate | Tissue-specific acidification assays |\n\n### Timeline/Cost: REALISTIC FOR REPURPOSING\n- **Repurposing pathway:** 3-4 years to Phase 2 (existing safety data)\n- **De novo development:** 7-9 years for novel TFEB activators\n- **Estimated cost:** $15-30M (repurposing) / $80-120M (de novo)\n\n**Recommendation:** Perform falsifying experiment with constitutively nuclear TFEB before committing resources. If flux remains impaired, deprioritize.\n\n---\n\n## Hypothesis 2: PP2A/Bβ1 Targeting ULK1\n**Survival Status: Weak**\n**Revised Confidence: 0.40-0.50**\n\n### Druggability: LOW-MODERATE\n**Critical Gap:** The hypothesis lacks mechanistic specificity for how PP2A-Bβ1 discriminates ULK1-S757 over S317. Without structural data on the PP2A-Bβ1:ULK1 interface, rational drug design is impossible.\n\n| Approach | Feasibility | Gap |\n|----------|-------------|-----|\n| Pan-PP2A inhibitors (LB-100) | Achievable | Lacks neuronal Bβ1 selectivity; cross-tissue toxicity |\n| Bβ1-selective compounds | Requires structural biology first | No structural data on Bβ1 regulatory subunit binding |\n| CRISPRi PPP2R2B | Technically feasible | Not druggable for chronic ALS treatment |\n\n### Biomarkers & Model Systems: MODERATE\n- **Phospho-ULK1 S757:** Phospho-specific antibodies exist; technically quantifiable\n- **PP2A-Bβ1 interaction with ULK1:** Requires IP-mass spectrometry validation (proposed experiment is sound)\n- **Model systems:** iPSC-derived motor neurons suitable; fibroblasts as controls\n\n### Clinical Development Constraints: HIGH\n- **Specificity problem:** PPP2R2B is \"neuron-enriched\" not \"neuron-exclusive.\" Non-neuronal cells expressing this subunit should show similar resistance if this is primary—yet rapamycin induces autophagy in hepatocytes.\n- **Mechanistic ambiguity:** Whether AMPK activators work in neurons depends on whether they bypass PP2A-Bβ1 (via S317) or overcome it (via unclear compensation). The cited evidence does not resolve this.\n- **Target validation sequencing:** Must confirm structural interface before clinical investment\n\n### Safety: UNCERTAIN\nLB-100 shows acceptable safety in oncology trials, but:\n- PP2A has broad substrates beyond ULK1\n- Neuronal PP2A regulates synaptic proteins (PPP2R2A, not Bβ1, but isoform specificity unclear)\n- Long-term safety in CNS application untested\n\n### Timeline/Cost: HIGH RISK\n- **6-8 years",
  "tokens_used": "1229",
  "persona_id": "persona-domain_expert"
}